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Atherosclerosis continues to be the leading cause of cardiovascular disease. Development
of atherosclerosis depends on chronic inﬂammation in the aorta and multiple immune cells
are involved in this process. Importantly, resident macrophages and dendritic cells (DCs)
are present within the healthy aorta, but the functions of these cells remain poorly charac-
terized. Local inﬂammation within the aortic wall promotes the recruitment of monocytes
and DC precursors to the aorta andmicro-environmental factors direct the differentiation of
these emigrated cells into multiple subsets of macrophages and DCs. Recent data suggest
that several populations of macrophages and DCs can co-exist within the aorta. Although
the functions of M1, M2, Mox, and M4 macrophages are well characterized in vitro, there
is a limited set of data on the role of these populations in atherogenesis in vivo. Recent
studies on the origin and the potential role of aortic DCs provide novel insights into the
biology of aortic DC subsets and prospective mechanisms of the immune response in ath-
erosclerosis. This review integrates the results of experiments analyzing heterogeneity of
DCs and macrophage subsets in healthy and diseased vessels and brieﬂy discusses the
known and potential functions of these cells in atherogenesis.
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THE DISCOVERY OF MACROPHAGES AND DENDRITIC CELLS
WITHIN THE AORTA
For almost a century, macrophages have been known to be
the cells that are involved in atherosclerosis. Anitschkow (1913)
discovered that early and advanced atherosclerotic plaques are
developed in direct correlation with the amount of dietary cho-
lesterol. Anitschkow also identiﬁed some lesional leukocytes as
“large cells with a foamy protoplasma” containing cholesterol
derivates in small vacuoles, which he considered to be derived
from blood lymphocytes or Langerhans’ cells. He named these
cells “cholesterolesterphagocytes,” based on their probable etiol-
ogy and assumed function. The idea that monocytes are involved
in the induction and persistence of atherosclerosis was exten-
sively studied during the following decades and this hypothesis
received additional conﬁrmation from various immunohisto-
chemical studies. Hoff (1972) reported the existence of mononu-
clear cells that were ultrastructurally identiﬁed as monocytes
by the presence of cytoplasmic peroxisomes in the intima, in
endothelial junctions, and among the endothelium of human
aortas obtained at autopsy. In an electron-microscopic survey
of the aorta in the adult rat, white blood cells were found to
adhere to the intima;whichwere invariably lymphocytes ormono-
cytes (Joris et al., 1979). Alpha-naphtyl acetate esterase-positive
(ANAE) monocytes were also detected within the central and
peripheral areas of lesions within rabbit aortas (Hansson et al.,
1980). Further characterization of these cells provided evidence
suggesting the existence of aortic macrophages (MΦ; Gerrity,
1981; Jonasson et al., 1986) and CD1a+ dendritic cells (DCs;
Bobryshev and Lord, 1998) within the subendothelial space of the
intima.
VASCULAR DENDRITIC CELLS IN HEALTHY AORTAS
The phenotype and markers of identiﬁcation vary for MΦs and
DCs within several tissues and often depend on the degree of mat-
uration and activation (Mosser and Edwards, 2008; Geissmann
et al., 2010). With respect to DCs located within the aorta, sev-
eral studies have reported unique features of human aortic DCs
that express CD1a+S-100+lag+CD31−CD83−CD86− and resem-
ble Langerhan’s cells (Bobryshev, 2010). These vascular-associated
DCs were named vascular DCs (Bobryshev and Lord, 1995). Addi-
tional seminal studies demonstrated the presence of resident DCs
in apparently healthy, non-diseased aortas (Bobryshev and Lord,
1995; Waltner-Romen et al., 1998; Millonig et al., 2001; Ma-Krupa
et al., 2004). Interestingly, DCs display distinct anatomical fea-
tures when located at different layers of the aorta, and probably
the adventitia as well. Structurally low-differentiated DCs are pre-
dominantly found in close proximity to the endothelium within
the normal intima, whereas DCs with a moderately developed
tubulovesicular system are localized throughout the thickness of
the tunica intima, mostly being concentrated in the subendothe-
lial space (Bobryshev, 2010), suggesting distinct structural and
probably functional differences between subsets of DCs located at
different areas of the aortic wall.
Recent studies using advanced techniques such as confocal
microscopy, monocyte-labeling technique, and ﬂow cytometry-
based analysis have further provided fascinating data about the
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accumulationof DCs andMΦwithin thehealthy artery. Flowcyto-
metric analysis of C57BL/6 aortas clearly demonstrated the pres-
ence of aortic CD11c+CD40+ cells (Galkina et al., 2006). How-
ever, as whole aortas were digested with enzymes, this approach
permitted the characterization of leukocytes within the aorta,
but did not provide data about the anatomical distribution of
DCs within the aortic wall. Additional studies utilizing confo-
cal microscopy revealed the presence of bone-marrow-derived
CD11c+ cells within the intima of healthy aortas of C57BL/6 mice
(Jongstra-Bilen et al., 2006).
Why would DCs accumulate within the healthy non-diseased
artery? It is well-known that atherosclerosis is a site-speciﬁc disease
characterized by the preferential development of plaques at the
lesser curvature of the aorta, and that ﬂow-dependent activation of
the aortic endothelium is partially responsible for the accelerated
recruitment of monocytes and DC-precursors to atherosclerosis-
prone areas. Interestingly, an abundance of CD68+CD11c+ cells,
but not CD68+ macrophages were detected within the lesion-
susceptible lesser curvature of the healthy aortic intima (Jongstra-
Bilen et al., 2006). Thus, the initial localization of intimal CD11c+
cells is determined by the micro-environment at speciﬁc anatom-
ical locations. However, the site-speciﬁc localization of intimal
CD11c+ cells occurs independent of circulating cholesterol levels,
highlighting the importance of blood ﬂow patterns rather than
plasma lipid levels in the direction of DC localization within the
aorta. Additional characterization of DCs by Choi et al. (2009)
revealed preferential accumulation of these cells within the car-
diac valve and aortic sinus of C57BL/6 mice. These aortic DCs
expressed low levels of CD40 and were positive for CD1d, CD80,
and CD86 antigens, suggesting that they possess an immature DC
phenotype (Table 1).
CD11c is not a unique marker for DCs, since some subsets of
MΦs are CD11c+ (Geissmann et al., 2010). Until recently, ques-
tions concerning the origin and sub-type of intimal CD11c+ cells
that reside within healthy aortas were unresolved. DCs are gener-
ated at least by two major pathways that differ in their requirement
for the Flt3/Flt3 ligand (Flt3L) axis. Development of DCs from
monocyte-independent precursors is Flt-3/Flt3L-dependent (Naik
et al., 2006; Onai et al., 2006; Liu et al., 2009), whereas the gener-
ation of DCs from monocytes is Flt3/Flt3L-independent (Cheong
et al., 2010). To address the dilemma about the developmental
source of aortic CD11c+ cells, Choi et al. (2011) successfully
adapted a previously developed ﬂow cytometry-based approach
for the analysis of murine aortas (Galkina et al., 2006) and tested
the effects of Flt3 on the expansion of aortic CD11c+ cells. Flt3
treatment resulted in an expansion of CD11c+ cells within the
intima and adventitia of C57BL/6 mice suggesting a DC origin of
CD11c+MHC-IIhigh cells.
Additional studies have also demonstrated the existence of
two major subsets of DCs as CD11c+CD11b+F4/80+ and
CD11c+CD11b−F4/80− cells within the aortas of C57BL/6 mice
(Table 1). CD11c+CD11b−F4/80− cells possessed a distinct phe-
notype characterized by CD103 and CD207 expression, and
were negative for CD8, CD205, CX3CR1, and 33D1 (Choi
et al., 2011). CD11c+CD11b+F4/80+CD103− DCs expressed the
CD14 co-receptor for TLR4 and DC-SIGN antigen (Table 1).
Development of these two subsets of DCs was considerably
different: CD11c+CD11b+F4/80+CD103− DCs were M-CSF-
dependent, and likely monocyte-derived DCs. In contrast,
CD11c+CD11b−F4/80−CD103+ DCs were Flt3-dependent DCs.
DC FUNCTIONS WITHIN HEALTHY AORTAS
The function of vascular DCs within healthy arteries remains
unclear; however, recent data suggest that widespread distribution
of HLA-DR-expressing cells within the healthy aortic intima may
play a role in the maintenance of vascular homeostasis (Bobryshev
et al., 2011). Similarly, CD11c+ DCs may play an active role dur-
ing the initial stages of atherosclerosis. Jongstra-Bilen et al. (2006)
demonstrated that aortic resident CD11c+ DCs actively uptake
neutral lipids within high cholesterol diet-fed Ldlr−/− mice. Fur-
thermore, as CD11c+ DCs are preferentially located within the
lesser curvature of the healthy aortas, the initial accumulation of
lipids is directed and regulated by CD11c+ intimal DCs within the
atherosclerosis-prone lesser curvature of the healthy aorta. Inter-
estingly, only a speciﬁc subset of CD11c+CD11b−33D1− DCs
accumulates lipids suggesting that there is a functional complexity
between DC subsets in the aorta, which is already reﬂected at the
levels of lipid uptake within relatively non-diseased vessels.
An important question concerning DC functions in athero-
sclerosis is whether these professional antigen-presenting cells are
capable of presenting antigens within the aortic wall. It has been
shown that adoptively transferred bone marrow-derived DCs,
activated with OVA peptide, induced profound proliferation of
TCR-speciﬁc lymphocytes that were detected in the spleen and
aortas of OT-I recipient mice (Galkina et al., 2006). These results
provided initial evidence that T cells residing within the aorta can
be activated by DCs, suggesting that this process may be important
in the initiation and/or progression of atherosclerosis. However,
this study did not directly address whether aortic DCs are capable
of presenting antigens to T cells. In a subsequent study, Choi et al.
(2009) convincingly showed that isolated aortic CD11c+ DCs are
able to present OVA peptide to OT-I and OT-II T cells in vitro and
in vivo. Importantly, these results correlate with experiments con-
ducted using a model of engineered bioartiﬁcial human arteries
that mimic the size and structural dimensions of human arteries.
Human CD11c+ DCs seeded within bioartiﬁcial arteries migrated
to the intima, where they triggered TLR-4-dependent T-cell acti-
vation, and initiated an adaptive immune response (Han et al.,
2008), suggesting that antigen presentation by human DCs can
occur in vivo.
ALTERATION OF DENDRITIC CELL POPULATIONS DURING
ATHEROGENESIS
The number of CD11c+ cells increases with the progression of
atherosclerosis in Apoe−/− mice (Galkina and Ley, 2009; Man-
they and Zernecke, 2011). DCs are detected in close proximity
to T cells in the zones of neovascularization within atheroscle-
rotic plaques, and near the vasa vasorum in the adventitia. In the
shoulder regions of unstable human plaques, CD83+ DCs are in
close proximity to CD40L+ T cells (Erbel et al., 2007). There is
an increasing number of studies that have focused on the mecha-
nisms underlying the accumulation of MΦs within atherosclerotic
aortas (Swirski et al., 2009; Ley et al., 2011); however, there is
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Table 1 | Location and DC phenotype in healthy and atherosclerotic aortas.
Dendritic cell phenotype Study population Locations Stages of
atherosclerosis
(demonstrated)
Reference
CD1a+S-100+ lag+CD31−CD83−CD86− DCs Humans Aortic intima Bobryshev and Lord (1995)
IFNα+ plasmacytoid DCs Humans Carotid and coronary
arteries
Type IV–V and VI Erbel et al. (2007), Niessner
et al. (2006)
CD11c+CD40+ DCs C57BL/6 mice Aorta Type 0-I Galkina et al. (2006)
CD11c+CD68+ DCs C57BL/6 mice Aortic intima (lesser
curvature)
Type 0-I Jongstra-Bilen et al. (2006)
CD11c+CD40lowCD1d+ CD80+ CD86+
(immature DCs)
C57BL/6 mice Aorta, aortic sinus
and cardiac valve
Type 0-I Choi et al. (2009)
CD11c+MHC-
II+CD11b−F4/80−CD207+CD103+ DCs
(Flt-3-dependent, Mn-independent precursors)
C57BL/6 mice Aorta Type 0-I Choi et al. (2011)
CD11c+MHC-II+CD11b+F4/80+
CD14+CD103−DC-SIGN+ DCs
(M-CSF-dependent, Mn-dependent)
C57BL/6 mice Aorta Type 0-I Choi et al. (2011)
CD11c+CD11b−CD68+MHC-II+33D1+ DCs
(GM-CSF-dependent proliferation in response
to cholesterol)
Ldlr−/− mice (40%
fat, 1.25% cholesterol,
1–3weeks)
Aortic intima Type 0-I Zhu et al. (2009)
CD11c+CD11b+CD8α−CD115−F4/80−440c−
PDCA-1− CCL17+ DCs
Apoe−/− mice (21%
fat, 0.15% cholesterol,
8–12weeks)
Aorta and aortic root Type I–IV Weber et al. (2011)
CD11clowB-220+CD11b−PDCA-1+ DCs Ldlr−/− mice (0.25%
cholesterol, 8weeks)
Aorta Type I–IV Daissormont et al. (2011)
still limited information about the potential mechanisms of aor-
tic DC accumulation in atherogenesis. Increased DC numbers
may be due to increased migration from peripheral circulation,
reduced emigration out of the vessel wall or increased local prolif-
eration. A recent study clearly demonstrated that at least for a spe-
ciﬁc subset of intimal CD11c+CD11b−CD68+MHC-II+33D1+
DCs, increased granulocyte/macrophage colony-stimulating fac-
tor (GM-CSF)-dependent proliferation might be a reason for
elevated levels of intimal DCs in the aorta of Ldlr−/− mice after
a short-term high cholesterol diet (Zhu et al., 2009). Interest-
ingly, aortic CD11c+CD11b− DCs proliferate independently from
Ly6Chigh monocytes, as BrDU+-proliferating DCs are detected
even after PTX-induced blockade of monocyte recruitment to the
aorta (Zhu et al., 2009).
Additional characterization of aortas isolated from Ldlr−/−
mice fed a high-fat cholesterol diet for 16weeks further shed
light on the dynamics of DC subset accumulation within the
aorta (Choi et al., 2009). Unexpectedly, both subsets of aor-
tic CD11c+MHC-II+CD11b+F4/80+ DCs and CD11c+MHC-
II+CD11b−F4/80−CD103+ DCs were elevated in atherosclerotic
aortas of Ldlr−/− mice (Choi et al., 2009). To further address
questions about the origin of intimal DC subsets, Choi et al.
(2011) generated Flt3−/−Ldlr−/− mice and investigated the dis-
tribution of DC subsets within the aortic intima of atherosclerotic
aortas. The numbers of CD11c+CD11b−CD103+ DCs, but not
CD11c+CD11b+CD103− DC, were reduced in Flt3−/−Ldlr−/−
mice, suggesting that aortic CD11c+CD11b−CD103+ DCs are
generated from a Flt3-dependent DC precursor.
POSSIBLE IMPLICATION OF DENDRITIC CELLS IN
ATHEROSCLEROSIS
To date, there is strong evidence that DC subsets actively par-
ticipate in the positive and negative regulation of the immune
response. GM-CSF-dependent CD8α+33D1−DEC205+ r cells
induces high levels of Th1 cytokines IFNγ and IL-2, whereas
CD8α−33D1+DEC205− cells,which are FLT-3-dependent, induce
also large amounts of IL-4 and IL-10 (Pulendran et al., 1999). Plas-
macytoidDCs (pDCs) sense viral nucleic acids and produce a large
amount of type I interferons. But also can play an important role
in the induction of tolerance. Lung pDCs induce oral tolerance
(Lewkowich et al., 2008), where as gut-associated CD103+ DCs
play roles in the regulation of the balance between Tregs and Th1
cells (Annacker et al., 2005).
The identiﬁcation of DC functions in atherosclerosis has pre-
sented a considerable challenge, as aortic DCs display molecular
markers and features of several cell types and can be proba-
bly derived from multiple progenitors (Geissmann et al., 2010;
Niessner and Weyand, 2010). Nevertheless, recent studies have
ﬁrmly established the presence of DCs within the healthy and
atherosclerosis-prone aorta, and have started to address questions
about the functions of DC subsets in lymphoid organs and the
aorta in atherosclerosis (Randolph, 2009).
Several lines of evidence suggest that hypercholesterolemia
affects the ability of DCs to migrate from peripheral tissues to
draining lymph nodes during atherogenesis (Angeli et al., 2004).
Prolonged retention of MΦs and DCs might also support their
pro-inﬂammatory status and the progression of lesions within
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atherosclerotic aortas (Llodra et al., 2004). However, evidence
also suggests that DCs maintain their capacity to prime naïve
T cells under the conditions of hypercholesterolemia (Packard
et al., 2008). DCs isolated from Ldlr−/− or Apoe−/− mice efﬁ-
ciently induce T-cell proliferation, IFNγ, and TNFα production
after ex vivo co-culture with naïve CD4+ T cells (Packard et al.,
2008). It is worth noting that hyperlipidemia also increases the
levels of blood circulating CD11c+ monocytes and upregulates
their expression of CD11b and CD29. CD11c deﬁciency reduces
monocyte/macrophage accumulation in atherosclerotic lesions
and attenuates atherogenesis inCd11c−/−Apoe−/− mice fed a high-
fat diet. Interestingly, deﬁciency of CD11c decreases the ﬁrm arrest
of mousemonocytes to vascular cell adhesionmolecule-1 (VCAM-
1) and E-selectin in a shear ﬂow assay (Wu et al., 2009). Thus,
elevated cholesterol levels not only provide possible antigens for
DCs, but also regulate the accumulation of CD11c+ monocytes
and potentially DC numbers in the aortic wall.
Dendritic cells are specialized in capturing, processing, and
presenting antigen-derived peptides on major histocompatibil-
ity complex (MHC) molecules in vivo, thereby, allowing DCs to
shape T-cell responses to modulate immunity or tolerance (Stein-
man, 2007). Numerous bodies of evidence have demonstrated that
oxLDLplays a pivotal role in the formation of foamcells, induction
of vascular dysfunction, and the support of leukocyte migration
to the atherosclerosis-prone aorta (Matsuura et al., 2006). Impor-
tantly, modiﬁed lipids likely affect the maturation and phenotype
of DCs. OxLDL during the late stage of monocyte differentia-
tion gives rise to phenotypically mature DCs that secrete IL-12
but not IL-10, and support both syngeneic and allogeneic T-
cell stimulation (Perrin-Cocon et al., 2001). In contrast, oxidized
phospholipids (ox-PLs) alter DC activation and prevent their mat-
uration through the blockade of TLR-3- and TLR-4-dependent
induction of CD40, CD80, CD83, and CD86 (Bluml et al., 2005).
It remains to be determined if only speciﬁc sets of lipids affect DC
functions and whether distinct subsets of DCs respond selectively
to modiﬁed lipid loading.
oxLDL serves as a potential source of antigens in atheroscle-
rosis and DCs might present antigens derived from oxLDL to
induce a speciﬁc T-cell response.Additionally,not only oxLDL,but
also other antigens, including beta-2 glycoprotein I (β2GPI) and
heat shock proteins HSP-60 and HSP-65 activate T cells. Recently,
our understanding of the oxidation hypothesis of atherosclerosis
was altered and some attention has shifted toward native LDL, as
potential antigens for atherosclerosis. In the elegant and extensive
work by Hermansson et al. (2010), the authors focused on iden-
tifying the potential mechanism of oxLDL recognition by T cells
via generation of T-cell hybridomas from human apolipoprotein
B100 transgenic mice that were immunized with human oxLDL.
Unexpectedly, T-cell hybridomas responded to native and puriﬁed
LDL apolipoprotein ApoB100, but not to oxLDL, suggesting the
existence of an immune response against native LDL. Subsequent
studies have demonstrated that immunization with lipid-loaded
DCs resulted in various effects on the progression of atherosclero-
sis and localmodulationof inﬂammationwithin the aorticwall (de
Jager and Kuiper, 2011). However, despite important insights into
the biology of DCs, there are a limited number of studies that have
tested the effects of oxLDL and native LDL on DC functions, and
the consequences of modiﬁed lipiduptake forT-cell differentiation
and activation.
To investigate the role of CD11c+ DC in atherogenesis, Gautier
et al. (2009) generated a mouse model with the over-expression
of the anti-apoptotic gene hBcl-2 under the control of the CD11c
promoter. It should be noted that Bcl2 expression was not detected
on pDC and CD11b+F4/80+ monocytes indicating that in this
model, the major effects of Bcl2 over-expression were directed
toward CD11chighMHC-IIhigh cells. The CD11chighMHC-IIhigh
DC population was increased in DC-hBcl2 mice, and was associ-
ated with enhanced T-cell activation, elevated levels of Th1, Th17-
related cytokines, and increased production of Th1-driven IgG2c
antibodies. Unexpectedly, increased levels of CD11c+ cells also
resulted in reduced plasma cholesterol. In line with these results,
the depletion of DCs in hyperlipidemic CD11c-diphtheria toxin
receptor (DTR) Apoe−/− transgenic mice resulted in enhanced
cholesterolemia. These data suggest a strong relationship between
CD11c-expressing cells and cholesterol homeostasis. To date, the
mechanisms that regulate CD11c+ cell-dependent cholesterol
metabolism are unknown.
A new approach was recently taken to study the potential
implication of CD11c+CD11b−CD103+ classical DCs in athero-
sclerosis using Flt-3−/−Ldlr−/− mice (Choi et al., 2011).Deﬁciency
of Flt-3 and therefore, depletion of CD11c+CD11b−CD103+ DCs
resulted in increased plaque burden within the aortic sinus and
the aortic arch. This accelerated atherogenesis was accompanied
by the reduction of Treg in the aorta and increased levels of aortic
IFNγ and TNFα without signiﬁcant alteration in the lipid lev-
els (Choi et al., 2011). Thus, aortic CD11c+CD103+ DCs likely
function as tolerogenic DCs during atherosclerosis. Although tra-
ditionally viewed as the main inducers of immunity, DCs are also
important players in the induction and maintenance of periph-
eral self-tolerance (Steinman et al., 2003). As Treg cells are the key
component of a suppressor anti-atherogenic arm of the immune
response, aortic CD11c+CD103+ DCs may play an important role
in their generation. Recently another subset of CCL17-expressing
DCs was identiﬁed as an important player in atherosclerosis
(Weber et al., 2011). DC-derived CCL17 limited the expansion
of Tregs and increased the plaque burden. In contrast, block-
ing antibodies against CCL17 maintained Treg differentiation and
attenuated atherosclerosis. These new results suggest the existence
of a CCL17-speciﬁc DC subset that has the capacity to alter Treg
homeostasis in atherogenesis. To date, the mechanisms that con-
trol the number and suppressor functions of Tregs in atherosclero-
sis are not well understood, but the recently discovered functions
of CD11c+CD11b−CD103+ DCs and CCL17+DCs offer some
evidence to suggest that DC-mediated regulation of Treg occurs in
atherosclerosis.
PLASMACYTOID DCs
Recent studies have further characterized several subsets of DCs
and have resulted in a deeper understanding of the heterogene-
ity and origin of vascular DCs. pDCs are a distinct subset of
DCs specialized in direct virus TLR7, TLR8, and TLR9-dependent
recognition that results in rapid induction of high levels of type
I interferon (interferon α/β, IFN) and other cytokines. pDCs are
closely related to classical antigen-presenting DC, since these cells
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have some common developmental origin and genetic similar-
ity (Reizis et al., 2011). The characterization of pDC lineage has
presented a considerable challenge, as pDCs display molecular
markers and features of several cell types, and can be derived from
multiple progenitors. Typically, pDCs show only low expression
of CD11c, while this marker is abundantly expressed by myeloid
DCs (mDCs). Ironically, pDCs also express some lymphocyte anti-
gens including CD4, Rag-1, CD45RA/B220, and pIII transcript of
the MHC class II transactivator (CIITA). One of the remaining
enigmas of pDC biology concerns their ability to present anti-
gen (Villadangos and Young, 2008). pDCs are found to be weak
antigen-presenting cells compared with classical DCs. Instead,
pDCs are considered immunomodulating cells that can direct the
immune response by tipping the balance of T helper responses via
their secretion of type I interferons.
There are several lines of evidence suggesting that pDCs might
have a role in atherosclerosis. IFNα+ pDCs are detected within
atherosclerosis-prone vessels (Bobryshev and Lord, 1995;Niessner
et al., 2006; Daissormont et al., 2011), with preferential expres-
sion within the shoulder region of atherosclerotic plaques. One
of the important pieces of data to suggest a pro-inﬂammatory
role of pDCs came from a study demonstrating that type I IFNs,
released by pDCs, can induce the expression of tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) onCD4+ Tcells
(Niessner et al., 2006). Furthermore, adoptive transfer of human
plaque-isolated CD4+ T cells into immunodeﬁcient mice that are
engrafted with human atherosclerotic plaque results in apopto-
sis of VSMCs in a TRAIL-dependent manner (Sato et al., 2006).
Altogether, these series of experiments suggest an important link
between aortic pDCs, the induction of TRAIL on T cells, and
possible TRAIL-dependent T cell-induced apoptosis of VSMCs.
In addition to the activities of pDCs as an immunogenic cell
sentinel, pDCs can also act as tolerogeneic cells when express-
ing inducible tolerogenic enzyme indoleamine 2,3-dioxygenase
(IDO), the inducible costimulator ligand (ICOS-L), and/or the
programmed death 1 ligand (PD-L1), which mediates Treg devel-
opment (Colonna et al., 2004; Matta et al., 2010). A recent study
by Daissormont et al. (2011) further addressed the potential role
of pDCs and reported an anti-inﬂammatory activity of pDCs dur-
ing atherogenesis. Surprisingly, pDC depletion by 120G8 mAb,
which recognizes PDCA-1 (marrow stromal cell antigen 2, BST2),
a marker exclusively expressed on mouse pDC, increased plaque
burden in Ldlr−/− recipient mice (Daissormont et al., 2011).
This acceleration of atherosclerosis was accompanied by increased
T-cell proliferation,elevated IFNγproduction and reduced expres-
sion of IDO in pDCs isolated from lymphoid tissue. These results
highlight the tolerogenic functions of pDCs and suggest that
this subset of DCs may play an important role in maintaining
the balance between Th1 and Treg cells during atherogenesis in
aortas and secondary lymphoid organs. Eicosapentaenoic acid
(EPA) has beneﬁcial effects on cardiovascular diseases, although
the precise mechanism is unknown. Interestingly, the treatment
with EPA attenuates atherosclerosis and increases the number of
CD11c+CD80-CD86- DCs expressing IDO in the spleen, therefore
inducing tolerogenic phenotype of DCs (Nakajima et al., 2011).
Plasmacytoid DCs are not tolerogenic under basal, non-
stimulated conditions andhave shownno IDOexpression. Speciﬁc
engagement of B7-1 receptors by CD152-Ig (CTLA-4-Ig) or
CD200R1 by CD200-Ig lead to initiating of IDO-dependent tol-
erance (Reizis et al., 2011). Thus, the functional relationships
between pDCs roles as the inducers of the immune response versus
tolerance are dependent on multiple ligands and likely cytokines
that contribute to the expression of a tolerogenic phenotype by
pDCs.Although the somewhat current data about the role of pDCs
are debatable, they clearly emphasize the complexity of pDC func-
tions in atherosclerosis. It will be important to understand how
increased levels of potential antigens from the necrotic core and
the alterations in the T-cell response affect DC functions during
atherogenesis. Recent studies that have focused on the role of DCs
in atherosclerosis also raise the tantalizing question of whether the
antigen-presenting functions of DCs will be a key component in
the regulation of the immune response in atherosclerosis.
THE ROLE OF MACROPHAGES IN ATHEROSCLEROSIS
Macrophages (MΦ) were the ﬁrst inﬂammatory cells to be asso-
ciated with atherosclerosis, where they represent the major cell
type in atherogenesis and play important roles in the progres-
sion of the lesions. The essential role of MΦs in the initiation and
progression of atherosclerosis was initially demonstrated using M-
CSF-deﬁcient osteopetrotic (op) Apoe−/− mice, which resulted in
a dramatic 86% reduction in plaque volume (Smith et al., 1995).
More recently, a model of CD11b promoter-diptheria toxin trans-
genic Apoe−/− chimeric mice with CD11b-DTR bone marrow was
used to deplete CD11b+ cells and test the role of CD11b+ cells
in atherogenesis (Stoneman et al., 2007). CD11b+ cell depletion
signiﬁcantly affected plaque development and altered plaque com-
position in the early stages of atherogenesis. However, despite a
50% reduction of monocytes in mice with advanced plaques, the
depletion of CD11b+ cells had no effect on the extent of plaques
or the composition of advanced lesions. Because monocytes, MΦ,
neutrophils, and a subset of DCs express CD11b, and have been
implicated in the pathology of atherosclerosis, the speciﬁc con-
tributions of MΦ and MΦ subsets to the observed phenotypes
were uncertain. Using an analogous method, Paulson et al. (2010),
recently used CD11c-DTR Ldlr−/− chimeric mice to investigate
the role of CD11c+ DCs in atherogenesis (Gautier et al., 2009).
CD11c-DTR Ldlr−/− chimeric mice fed a cholesterol-rich diet for
5–10 days displayed a 55% reduction in intimal lipid area in com-
parison to un-depleted control mice, suggesting a pro-atherogenic
role for CD11c+ DCs. However, as foam cells can similarly express
CD11c, it is unclear whether the observed effects are due to the
removal of foam cells or the removal of DCs from the forming
atherosclerotic lesions.
MACROPHAGE SUBSETS
In the initial stages of atherogenesis, blood monocytes adhere
to and transmigrate through the endothelial cell layer to dif-
ferentiate into specialized mononuclear phagocytes. The process
of deriving polarized aortic MΦ and/or DCs from monocytes
involves a variety of factors including components of the extra-
cellular matrix, pro-inﬂammatory cytokines/chemokines, anti-
inﬂammatory cytokines/chemokines, oxidized or modiﬁed LDL,
and CD40/CD40L (Ley et al., 2011; Moore and Tabas, 2011).
Recently, the process of MΦ polarization during atherogenesis
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has been a subject of interest as MΦ subsets have been demon-
strated to display some degree of plasticity and heterogeneity
within atherosclerotic lesions (Ley et al., 2011; Moore and Tabas,
2011; Wolfs et al., 2011). Initially, a model of two modes of MΦ
activation was proposed to differentiate between inﬂammatory
MΦs (M1) and anti-inﬂammatory MΦs (M2; Gordon and Tay-
lor, 2005). Pro-inﬂammatory M1 MΦs were originally described
from studies conducted in the 1960s by Mackaness and colleagues
(Blanden et al., 1969) who demonstrated that murine MΦs dis-
played enhanced anti-microbial activity, in a stimulus dependent
manner, in response to Mycobacterium bovis bacillus Calmette–
Guerin (BCG) or Listeria monocytogenes infections (Blanden et al.,
1969). In contrast, Stein et al. (1992) demonstrated in 1992 that
MΦs could be polarized to an “alternative” state (M2) in the
presence of IL-4 characterized by expression of the macrophage
mannose receptor (CD206). More recently, with the addition of
the newer M2 subsets (M2a-c),Mox, and M4 subsets the paradigm
of MΦ activation has been further extended (Ley et al., 2011;Wolfs
et al., 2011).
M1 MACROPHAGES
Following the discovery that M1 and M2 MΦ subsets are gener-
ated in different inﬂammatory conditions, the attention of the ﬁeld
was directed toward investigating the generation, phenotype, and
possible functions of aortic MΦs during atherogenesis. In order
to better understand the properties of MΦ subsets and identify
new markers for the recognition of M2 MΦs, several approaches
for the generation of MΦ subsets were developed. To date, both
human and murine monocytes can be polarized into various
MΦ subsets in vitro depending on the culture conditions used.
Monocyte/macrophage colony-stimulating factor (M-CSF) is a
key cytokine for the generation of un-polarized MΦs from mono-
cytes in vitro (Stanley et al., 1978). Un-polarized MΦs can then be
driven toward polarizedMΦ subsets based on environmental cues.
M1 MΦs were originally derived and characterized through the
combined treatment of un-polarized MΦs with IFNγ and TNFα.
This treatment results in the generation of M1 MΦs that strongly
produce pro-inﬂammatory cytokines, including IL-1β, IL-6, IL-
8, IL-12, and TNFα, and possess enhanced microbicidal activity
(reviewed in Mosser and Edwards, 2008; Ley et al., 2011; Wolfs
et al., 2011). Similarly, the use of MyD88-dependent TLR agonists
and IFN-γ are effective in producing M1 MΦs in vitro (Mosser
and Edwards, 2008). M1 MΦs have been described to exert deﬁn-
itive pro-inﬂammatory roles, thereby worsening the progression
of autoimmune disorders like rheumatoid arthritis, Crohn’s dis-
ease, multiple sclerosis, or protecting the host from infectious
microorganisms (Murray and Wynn, 2011).
While information on the polarization of MΦs in vitro is use-
ful as a starting point, the situation in vivo is quite complex.
Following transmigration, monocytes can differentiate into MΦs
via intimal M-CSF (Smith et al., 1995). During this process, un-
polarized MΦs upregulate the expression of pattern recognition
receptors, including toll-like receptors, c-type lectin receptors,
scavenger receptors, retinoic acid-inducible gene 1-like helicase
receptors, and NOD-like receptors, in order to search the micro-
environment for pathogens, foreign substances, apoptotic cells,
and oxLDL (Murray and Wynn, 2011). In response to Th1, γδ T
cell,NK,andNKTcell-derived IFNγ andpro-inﬂammatoryTNFα,
MΦs can polarize toward a classic M1 phenotype that is character-
ized by high expression of macrophage receptor with collagenous
structure (Marco), suppressor of cytokine signaling 3 (Socs3),
inducible nitric oxide synthase (Nos2), TNF-α, IL-1β, IL-6, IL-
12, IL-23, cyclooxygenase 2 (Cox2), indoleamine 2,3-dioxygenase 1
(Ido1), and the production of reactive oxygen and nitrogen species
(Murray and Wynn, 2011). In the context of atherosclerosis, sev-
eral lines of evidence exist to suggest that M1 MΦs are located
within both human and murine atherosclerotic plaques. Bouhlel
et al. (2007) demonstrated the presence of CCL2+CD206neg M1
MΦs in human endartectomy specimens. In murine aortas, M1
MΦs are found in high-fat diet-fed Ldlr−/− aortas by immuno-
ﬂuorescence and ﬂow cytometry (Kadl et al., 2010). Interestingly,
Khallou-Laschet et al. (2010) demonstrated initial accumulation
of M2MΦs and further increased inM1MΦs within the advanced
lesions of Apoe−/− mice.
While the speciﬁc effects of M1-derived pro-inﬂammatory fac-
tors have not been assessed in atherosclerosis, in vitro data and
global cytokine knockout studies have provided some insight con-
cerning the functions that M1 MΦs may exert in situ. The effects
of TNFα and other pro-inﬂammatory cytokines on the vascular
endothelium and smooth muscle cell layer are well established.
As M1 MΦs secrete elevated levels of TNFα, IL-1β, and IL-6,
these M1-derived cytokines may play a role in further activating
endothelial and smooth muscle cells, resulting in the upregu-
lation of endothelial and smooth muscle cell chemokines; and
may play a role in endothelial dysfunction via down-regulation of
endothelial eNOS expression andROS/RNS driven oxidative stress
(Figure 1; Table 2). Similarly, M1 MΦs may play a role in driving
the generation of the pro-inﬂammatory Th1 cell and controver-
sial Th17 cell subsets, thereby promoting further inﬂammation
(Butcher andGalkina, 2011;Murray andWynn,2011). In addition,
as bone marrow macrophage-derived M1 MΦs strongly phago-
cytose oxLDL, secrete matrix metalloproteases (MMP1, MMP3,
and MMP9), and are poor efferocytes in vitro, M1 MΦs may
play a role in promoting the formation of a large necrotic core,
plaque destabilization, and thrombus formation (Ley et al., 2011;
Moore and Tabas, 2011; Murray and Wynn, 2011; Wolfs et al.,
2011).
M2 MACROPHAGES
M2 MΦs were originally derived from monocyte-derived MΦs
with M-CSF and IL-4 (Stein et al., 1992) and deﬁned based on
the expression of the macrophage mannose receptor (CD206);
however, more recent studies have found that MΦ phenotypes
reminiscent of M2 MΦs can also be produced in vitro. In vitro,
alternative MΦs (M2a) can be polarized using M-CSF and the
Th2-related cytokines IL-4 or IL-13. Similarly, the M2b pheno-
type can be obtained in the presence of immune complexes and
IL-1β or LPS,whileM2cMΦs can be derived using IL-10,TGFβ, or
glucocorticoids (Mosser and Edwards, 2008; Ley et al., 2011;Wolfs
et al., 2011). What would be a source of M2 cytokines within the
atherosclerotic aorta? Mast cells and Th2 cells are found within
atherosclerotic aortas and can serve as a potential source of IL-1β,
IL-4, IL-13, and IL-10 cytokines, which may in turn polarize MΦs
toward alternative activation phenotypes.
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FIGURE 1 | Potential functions of macrophage polarization states
in atherosclerosis. Upon activation, macrophages can assume
different polarization states in response to environmental cues, which
may have various effects on the components of atherosclerotic
plaques.While M1, M2, and Mox/Mha subsets have been shown to
exist in atherosclerotic plaques, the presence of M4 macrophages have
yet to be shown. Macrophage-derived cytokines, chemokines, other
factors, and possible effects are listed in the box. ↑, increase; ↓,
decrease; →, result or effect; CO, carbon monoxide; EC, endothelial
cell; eNOS, endothelial nitric oxide synthase; HO-1, heme oxygenase-1;
ICAM-1, intercellular adhesion molecule 1; MΦ, macrophage; MMP,
matrix metalloproteinase; SMC, smooth muscle cell; Srxn1,
sulﬁredoxin 1 homolog; Txnrd1, thioredoxin reductase 1; VCAM-1,
vascular cell adhesion molecule 1.
In contrast to pro-inﬂammatory M1, M2 MΦs have been
described as wound-healing MΦs, based on their ability to pro-
mote wound healing through matrix remodeling, efferocytosis,
and the recruitment of ﬁbroblasts (Gordon and Martinez, 2010;
Murray and Wynn, 2011). In general, M2 MΦs characteristically
express CD206, resistin-like molecule alpha (Relma; Fizz1), sup-
pressor of cytokine signaling 2 (Socs2), interferon regulatory factor
4 (Irf4), chitinase, acidic (Chia), chitinase 3-like protein 2 (Chi3l1;
Gp39, Ykl40), chitinase 3-like protein 2 (Chi3l2; Ykl39), chitinase
3-like protein 3 (Chi3l3; Ym1), CXCL13, CCL12, CCL24, and
Krüppel-like factor 4 (Klf4; Murray and Wynn, 2011), which can
be used to identify them in vivo (Table 2). In the context of ath-
erosclerosis, M2 MΦs have been observed within both human
and murine atheroma. Bouhlel et al. (2007) ﬁrst demonstrated
the presence of CD206+ M2 MΦs within human endarterectomy
specimens in the stable areas of the plaque. Chinetti-Gbaguidi
et al. (2011) demonstrated that CD68+CD206+ M2 MΦs, which
localized far from the lipid core in comparison to CD68+CD206−
M1 MΦs, contained smaller lipid droplets as demonstrated by Oil
red O staining.
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Similar to M1 MΦs, while the effects of M2-secreted cytokines,
chemokines, and small molecules have not been speciﬁcally
assessed in atherosclerosis, in vitro data and global cytokine knock-
out studies have provided some insight concerning the possi-
ble functions M2 MΦs in vivo (Figure 1). Depending on the
conditions in vitro, M2 MΦs may produce anti-inﬂammatory
cytokines including, IL-4, IL-13, IL-10. Based on studies of global
cytokine knockout mice in atherosclerosis (Kleemann et al.,
2008), M2 MΦ-derived IL-4, IL-13, and IL-10, through their
immunosuppressive effects on T cell and MΦ activation, may
lead to decreased endothelial cell and smooth muscle cell activa-
tion; leading to decreased pro-inﬂammatory chemokine expres-
sion, increased endothelial eNOS expression, vasorelaxation, and
smooth muscle cell proliferation (Figure 1; Table 2). Addi-
tionally, M2-secreted IL-4, IL-13, and IL-10 may support the
generation of anti-inﬂammatory Th2 cells and immunosuppres-
sive Treg, favoring alternative inﬂammation. In contrast to M1
MΦs, bone marrow-derived M2 MΦs are unable to phagocy-
tose oxLDL efﬁciently but are highly effective efferocytes that
secrete a variety of matrix metalloproteases (MMP2, MMP9,
MMP12, MMP13, MMP14), suggesting that M2 MΦs may pro-
mote the clearance of apoptotic cells in early atherosclerotic
plaques but could destabilize the plaque in the advanced stages
of the disease.
Mox/Mha SUBSET OF MACROPHAGES
Recently, an additional MΦ subset, namely Mox MΦs, has been
proposed (Kadl et al., 2010). Un-polarized bone marrow-derived
MΦ cultures that were treated with the ox-PL 1-palmitoyl-
2arachidonoyl-sn-glycero-3-phosphorylcholine generated a pop-
ulation of MΦs that expressed a unique proﬁle of genes including
Heme oxygenase-1 (HO-1), suﬁredoxin-1 (Srnx1), and thiore-
doxin reductase 1 (Txnrd1) in a nuclear factor, erythroid-derived
2, like 2 (Nrf2) dependent manner (Kadl et al., 2010). This pop-
ulation of Mox MΦs was also found within the aortas of 30
week western diet-fed Ldlr−/− mice by immunohistochemistry
and ﬂow cytometry. In addition to their hallmark expression of
HO-1,Mox MΦs expressed the anti-oxidant enzymes Txnrd1, and
Srnx1 by immunoﬂuorescence. This unique population of Mox
(CD45+CD11b+F4/80+HO-1+ cells) MΦs comprised 23% of the
aortic CD11b+F4/80+ population. The remaining 39% of aor-
tic CD11b+F4/80+ cells were classiﬁed as CD11b+F4/80+CD86+
M1 MΦs and 22% expressed the M2 marker CD206 (Kadl et al.,
2010). The proposed phenotype of MoxMΦs closely resembles the
phenotype of the recently proposed hemorrhage-associated MΦs
(Mha; Boyle et al., 2009; Boyle et al., 2011). Human monocyte-
derived MΦs that are treated in vitro with hapto-hemoglobin
complexes or oxidized red blood cells were found to upregulate
CD163, HO-1, and IL-10 in an Nrf2-dependent manner (Boyle
et al., 2009). These CD163+CD68+ MΦs were associated with the
ﬁbrous cap region and regions of hemorrhagewithin human coro-
nary artery plaques. These results suggest that Mox MΦs, which
are present within the atherosclerotic mouse lesions, are pheno-
typically similar to Mha MΦs, and underscore the heterogeneity
of MΦs with atherosclerotic vessels.
At present, little is known about the functionality of Mox/Mha
MΦs in vivo (Figure 1). As Mox/Mha MΦs express IL-10, VEGF,
and enzymes with anti-oxidizing activities, they may exert anti-
inﬂammatory actions on the vasculature in vivo. In this regard,
HO-1, Srxn1, and Txnrd1, through the sequestration of iron, the
production of bilirubin, and carbon monoxide (Otterbein et al.,
2003; Wolfs et al., 2011), may protect endothelial cells and smooth
muscle cells from oxidative stress and promote vasorelaxation
through the production of carbon monoxide (Figure 1; Table 2).
In addition, Mox/Mha-derived IL-10 and VEGF may play anti-
inﬂammatory roles through the suppression of T-cell and MΦ
activation, and the promotion of endothelial cell proliferation and
survival, respectively (Kadl et al., 2010; Wolfs et al., 2011). How-
ever,data from in vitro phagocytosis assays demonstrated thatMox
MΦs are poor efferocytes and are only weakly able to phagocytose
oxLDL, suggesting that Mox/Mha MΦs may not be able to effec-
tively clear apoptotic cells and resolve inﬂammation in vivo (Kadl
et al., 2010; Wolfs et al., 2011).
M4 MACROPHAGES
Recently, Gleissner et al. (2010b) identiﬁed a unique subset of M-
CSF/CXCL4-dependent macrophages that was termed M4 MΦs.
M4 MΦs expressed a unique set of transcripts, including higher
levels of Cd86, tumor necrosis factor (ligand) superfamilymember
10 (Tnfsf10), mannose receptor, c type 1 (Mrc1), Ccl18, Ccl22, Tnf,
and lower levels of pentraxin 3 (Ptx3),Cd36, and Il10. In this study,
M4 MΦs were weakly phagocytic and unable to efﬁciently phago-
cytize acLDL or oxLDL, suggesting that M4 MΦs may not readily
become foam cells or function as efferocytes within atherosclerotic
plaques. The functions of M4 MΦs remains poor understood. In
the context of atherosclerosis, atherosclerotic lesions have been
demonstrated to contain M1, M2, and M4 marker-expressing
MΦs, suggesting that the pool of lesional MΦs may play different
roles in the pathology of atherosclerosis (Figure 1; Table 2). For
more information on M4 MΦs we refer the reader to the pertinent
review by C. Gleissner in this issue.
MIXED PHENOTYPE AND PLASTICITY OF MACROPHAGE
SUBSETS
Although the in vitro conditions of generation of MΦ subsets
are very distinct and require speciﬁc sets of cytokines, several
subsets of MΦs likely exist simultaneously within atheroscle-
rotic aortas in vivo. As alluded to in the preceding sections, the
murine and human atherosclerotic plaque MΦ pool is, in real-
ity, comprised of a complex mixture of MΦ subsets; which work
together to result in the progression and persistence of athero-
sclerotic plaques. There is some evidence, mainly from in vitro
studies, to suggest that the phenotypes of MΦ subsets are not
ﬁxed, and that these cells possess some phenotypic plasticity in
response to micro-environmental factors. For example, Khallou-
Laschet et al. (2010) reported that bone marrow-derived MΦs
from C57BL/6 and Apoe−/− mice driven to M1 or M2 phenotypes
are able to assume the opposing phenotype (M2 or M1, respec-
tively) when the culture conditions are switched. This idea is also
supported by the work of Feig et al. (2011), in which murine
aortic sections were examined for the expression of M2 MΦ
markers in amodel of athero-regression via laser capturemicrodis-
section. Apoe−/− aortic arches were transplanted into C57BL/6,
ApoAI−/−, human apoAI Apoe−/− transgenic, and Apoe−/− mice
www.frontiersin.org March 2012 | Volume 3 | Article 44 | 9
Butcher and Galkina Dendritic cells and macrophages in atherosclerosis
and assessed for pro-inﬂammatory chemokines, MHC, class 1-
related (Mr1), Cd163, C-lectin, and Fizz-1 expression 1-week post
transplantation. In this model, lesional CD68+ MΦs expressed
higher levels of M2 markers within athero-regressive C57BL/6
and hApoeAI Apoe−/− transgenic mice, suggesting that plaque
MΦs can assume a M2 phenotype in the athero-regressive state.
Recently in different system, Liao et al. (2011) examined the role
of Krüppel-like factor 4 (KLF-4) in MΦ polarization in vitro, and
in a model of diet-induced obesity. KLF4 was strongly induced in
M2 MΦs, where it interacted with Stat-6 to reinforce the expres-
sion of M2 genes and antagonized M1 gene expression via the
sequestration of co-activators of NF-kB activation in vitro. In
a model of diet-induced obesity, LysM-Cre-Klf4ﬂox/ﬂoxC57BL/6
bone marrow chimeras displayed signiﬁcant increases in total
body weight, subcutaneous and visceral fat depot sizes, glucose
intolerance, and insulin resistance, which corresponded with ele-
vated M1 related gene expression within the stromal vascular
fractions of LysM-CreKlf4ﬂox/ﬂoxC57BL/6 chimeras in compari-
son to Klf4ﬂox/ﬂoxC57BL/6 chimeras. These results suggest that
KLF4 may similarly play a role in the formation of M2 MΦs in
atherosclerotic plaques.
Thus, at present, the functions and speciﬁc contributions of
MΦ subsets to the pathogenesis of atherosclerosis are largely
unknown. While in vitro MΦ polarization and global cytokine
knockout studies have provided some mechanistic insight, novel
techniques to speciﬁcally target MΦ subsets or MΦ effector mol-
ecules are necessary to further clarify the roles of MΦ subsets
in atherosclerosis. In addition, anticipated follow-up studies of
Mox/Mha and M4 MΦ in atherosclerosis should help to clarify
the functions of these subsets in atherogenesis.
To date, it is clear that both MΦs and DCs display phe-
notypic and functional heterogeneity within atherosclerotic and
non-diseased arteries. However, as the majority of the studies
have examined either DC or macrophage heterogeneity at a sin-
gle time point, it is unclear how these two populations change
as atherosclerotic plaques develop and progress. According to the
American Heart Association guidelines for the histological clas-
siﬁcation of atherosclerotic plaques, there are six distinct stages
of atherosclerotic lesions (Stary et al., 1995). These stages range
from clinically silent initial (I), fatty streak (II), and intermedi-
ate lesions (III), to clinically overt atheroma (IV), ﬁbroatheroma
(V), and complicated lesions (VI). Mouse models of atherosclero-
sis, including Apoe−/− and Ldlr−/− mice, develop atherosclerotic
lesions in a similarmanner, ranging from initial (I), fatty streak (II)
lesions to intermediate (III), atheroma (IV), and ﬁbrous plaques
(V) (Nakashima et al., 1994). Thus,basedon these lesion stage deﬁ-
nitions,we have noted (Table 1) the stage(s) at which dendritic and
macrophage subsets have been observed. In general, while mouse
studies have primarily focused on DCs in the non-atherosclerotic
C57BL/6 aorta or initial stages of atherosclerosis in Apoe−/− and
Ldlr−/− mice, human studies have focused on vascular DCs within
late stage symptomatic or asymptomatic endarterectomy patients.
AsDC subsets have been shown to exert pro-inﬂammatory (Weber
et al., 2011) and tolerogenic (Choi et al., 2011) functions, examin-
ing the dynamics of DC subset recruitment and functions within
the aorta during atherogenesis will likely result in new therapeutic
opportunities for targeting pro-inﬂammatory DCs or developing
vaccines. Similarly, while MΦs represent the majority of leuko-
cytes within atherosclerotic plaques, the speciﬁc functions of
MΦ subsets have only recently come under consideration. While
macrophages are present throughout the development of athero-
sclerosis, little is known about the speciﬁc recruitment or egress of
M1 and M2 MΦs from atherosclerotic plaques.
CONCLUDING REMARKS
Our understanding of the mechanisms of atherosclerosis has
notably progressed in parallel with work adding to our under-
standing of immune system under homeostatic and inﬂamma-
tory conditions. Recent breakthrough discoveries on the plasticity
and heterogeneity of monocytes, MΦs, and DCs have opened
new directions for the investigation and further understanding
of the potential roles of multiple subsets of DCs and MΦs in
the initiation, maintenance and resolution of atherosclerosis. To
date, multiple lines of evidence clearly demonstrate that DCs and
MΦs represent heterogeneous populations with distinct pheno-
types in vitro and in vivo within atherosclerotic aortas. However,
the functions and speciﬁc mechanisms that control the gen-
eration of distinct MΦ and DC subsets within atherosclerotic
vessels are poorly understood. In this review, we have focused
on the characterization and potential implications of DC and
MΦ subsets within healthy and atherosclerotic aortas (Tables 1
and 2).
Our current understanding of the functions of MΦ subsets
in vivo relies heavily upon their generation and functions in vitro,
as well as, the effects of global cytokine, chemokine, and enzyme
knockouts, rather than the effects of MΦ subset-speciﬁc knock-
outs. Cell-type speciﬁc knockouts using the Cre-Lox recombina-
tion strategy and transgenic mice have been used to speciﬁcally
knockout genes within myeloid cells; however, as the expression
proﬁles of different myeloid cells can be fairly similar, unintended
effects can occur. Unfortunately, at present, MΦ subset-speciﬁc
Cre-mice have not been reported, and the precise functions of
MΦ subsets in vivo remain somewhat elusive.
What may we conclude at the present time about the effects
of different subsets of DCs and MΦs on the biology of the
aorta? First, distinct subsets of resident aortic DC and MΦs
may be important contributors to balancing the activation and
suppressor arms of the immune response within the normal,
non-inﬂamed aorta. Additional studies that will be devoted to
the biology of healthy aortas should clarify the consequences of
early events during the induction of atherosclerosis, and iden-
tify unique roles for each subset of DC and MΦ for each step
of atherosclerosis. As atherosclerosis is an age- and time-related
disease, the kinetics of induction and the molecular and cel-
lular events that underlie these events are important and may
provide novel therapeutic opportunities. Second, several intrigu-
ing studies have suggested that MΦs and DCs are comprised
of a diverse group of cells in atherosclerosis. DC subsets are
found within healthy and atherosclerosis-prone aortas and under-
standing how different subsets of DCs respond to lipid uptake
will help to advance the ﬁeld. It is unclear if all DCs serve as
antigen-presenting cells, and very little is currently known about
a preferential subset of DCs that is responsible for T cell-induced
inﬂammation within the aorta. Similarly, several subsets of MΦs
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are present within healthy and atherosclerotic arteries. While M1
MΦs likely play a critical role in the pathology of atherosclero-
sis, the relationship between M1 MΦs and other MΦ subsets,
as well as the possibility of phenotypic plasticity within athero-
sclerotic plaques are unknown. Third, it would be important to
identify the pathway(s) through which CD11c+ cells may modu-
late the levels of plasma cholesterol. Additionally, while we have
considerable knowledge about the recruitment of monocyte sub-
sets to and exit from the atherosclerotic plaques, it is still uncertain
whether the efﬂux or retention of DCs is regulated by the plasma
cholesterol levels. Finally, DC-based vaccination provides some
promising data for the treatment of atherosclerosis, but several
questions such as speciﬁcity of antigens, choice of adjuvants and
optimal type of DCs used for vaccination remain to be better
investigated.
ACKNOWLEDGMENTS
This work was supported by American Heart Association Pre-
doctoral Fellowship grant 11PRE7520041 (to Matthew Butcher)
and by the NHLBI HL107522 (to Elena Galkina).
REFERENCES
Angeli, V., Llodra, J., Rong, J. X., Satoh,
K., Ishii, S., Shimizu, T., Fisher, E. A.,
and Randolph, G. J. (2004). Dyslipi-
demia associated with atheroscle-
rotic disease systemically alters den-
dritic cell mobilization. Immunity
21, 561–574.
Anitschkow, N. (1913). Uber die veran-
derungen der kaninchenaorta bei
experimenteller cholesterinsteatose.
Beitr. Pathol. Anat. 56, 379–404.
Annacker, O., Coombes, J. L., Malm-
strom, V., Uhlig, H. H., Bourne, T.,
Johansson-Lindbom, B., Agace, W.
W., Parker, C. M., and Powrie, F.
(2005) Essential role for CD103 in
the T cell-mediated regulation of
experimental colitis. J. Exp. Med.
202, 1051–1061.
Blanden, R. V., Lefford, M. J., and
Mackaness, G. B. (1969). The host
response to Calmette-Guerin bacil-
lus infection in mice. J. Exp. Med.
129, 1079–1107.
Bluml, S., Kirchberger, S., Bochkov,
V. N., Kronke, G., Stuhlmeier, K.,
Majdic, O., Zlabinger, G. J., Knapp,
W., Binder, B. R., Stockl, J., and
Leitinger, N. (2005). Oxidized phos-
pholipids negatively regulate den-
dritic cell maturation induced by
TLRs and CD40. J. Immunol. 175,
501–508.
Bobryshev, Y. V. (2010). Dendritic cells
and their role in atherogenesis. Lab.
Invest. 90, 970–984.
Bobryshev, Y. V., and Lord, R. S. (1995).
Ultrastructural recognition of cells
with dendritic cell morphology in
human aortic intima. Contacting
interactions of vascular dendritic
cells in athero-resistant and athero-
prone areas of the normal aorta.
Arch. Histol. Cytol. 58, 307–322.
Bobryshev, Y. V., and Lord, R. S. (1998).
Mapping of vascular dendritic cells
in atherosclerotic arteries suggests
their involvement in local immune-
inﬂammatory reactions. Cardiovasc.
Res. 37, 799–810.
Bobryshev, Y. V., Moisenovich, M. M.,
Pustovalova, O. L., Agapov, I. I., and
Orekhov, A. N. (2011). Widespread
distribution of HLA-DR-expressing
cells in macroscopically undiseased
intima of the human aorta: A pos-
sible role in surveillance and main-
tenance of vascular homeostasis.
Immunobiology 22.
Bouhlel, M. A., Derudas, B., Riga-
monti, E., DiFvart, R., Brozek, J.,
Haulon, S., Zawadzki, C., Jude,
B., Torpier, G., Marx, N., Staels,
B., and Chinetti-Gbaguidi, G.
(2007). PPAR[gamma] Activation
Primes Human Monocytes into
Alternative M2 Macrophages with
Anti-inﬂammatory Properties. Cell
Metab. 6, 137–143.
Boyle, J. J., Harrington, H. A., Piper,
E., Elderﬁeld, K., Stark, J., Lan-
dis, R. C., and Haskard, D. O.
(2009). Coronary intraplaque hem-
orrhage evokes a novel atheroprotec-
tive macrophage phenotype. Am. J.
Pathol. 174, 1097–1108.
Boyle, J. J., Johns, M., Lo, J., Chio-
dini, A., Ambrose, N., Evans, P. C.,
Mason, J. C., and Haskard, D. O.
(2011). Heme induces heme oxy-
genase 1 via Nrf2: role in the
homeostatic macrophage response
to intraplaque hemorrhage. Arte-
rioscler. Thromb. Vasc. Biol. 31,
2685–2691.
Butcher, M., and Galkina, E. (2011).
Current views on the functions of
interleukin-17A-producing cells in
atherosclerosis. Thromb. Haemost.
106, 787–795.
Cheong, C., Matos, I., Choi, J. H., Dan-
damudi, D. B., Shrestha, E., Longhi,
M. P., Jeffrey, K. L., Anthony, R. M.,
Kluger, C., Nchinda, G., Koh, H.,
Rodriguez, A., Idoyaga, J., Pack, M.,
Velinzon, K., Park, C. G., and Stein-
man R. M. (2010). Microbial stim-
ulation fully differentiates mono-
cytes to DC-SIGN/CD209(+) den-
dritic cells for immune T cell areas.
Cell 143, 16–29.
Chinetti-Gbaguidi, G., Baron, M.,
Bouhlel, M. A., Vanhoutte, J., Copin,
C., Sebti, Y., Derudas, B., Mayi, T.,
Bories, G., Tailleux, A., Haulon, S.,
Zawadzki, C., Jude, B., and Staels,
B. (2011). Human atherosclerotic
plaque alternative macrophages dis-
play low cholesterol handling but
high phagocytosis because of dis-
tinct activities of the PPARgamma
and LXRalpha pathways. Circ. Res.
108, 985–995.
Choi, J. H., Cheong, C., Dandamudi,
D. B., Park, C. G., Rodriguez, A.,
Mehandru, S., Velinzon, K., Jung, I.
H., Yoo, J. Y., Oh, G. T., and Stein-
man, R. M. (2011). Flt3 signaling-
dependent dendritic cells protect
against atherosclerosis. Immunity
35, 819–831.
Choi, J. H., Do, Y., Cheong, C., Koh,
H., Boscardin, S. B., Oh, Y. S., Boz-
zacco, L., Trumpfheller, C., Park, C.
G., and Steinman, R. M. (2009).
Identiﬁcation of antigen-presenting
dendritic cells in mouse aorta and
cardiac valves. J. Exp. Med. 206,
497–505.
Colonna, M., Trinchieri, G., and Liu,
Y. J. (2004). Plasmacytoid dendritic
cells in immunity. Nat. Immunol. 5,
1219–1226.
Daissormont, I. T., Christ, A., Temmer-
man, L., Sampedro, M. S., Seijkens,
T., Rousch, M., Poggi, M., Boon, L.,
van der Loos, C., Daemen, M., Lut-
gens, E., Halvorsen, B., Aukrust, P.,
Janssen, E., and Biessen, E.A. (2011).
Plasmacytoid dendritic cells protect
against atherosclerosis by tuning T-
cell proliferation and activity. Circ.
Res.109, 1387–1395.
de Jager, S. C., and Kuiper, J. (2011).
Vaccination strategies in athero-
sclerosis. Thromb. Haemost. 106,
796–803.
Erbel, C., Sato, K.,Meyer, F. B., Kopecky,
S. L., Frye, R. L., Goronzy, J. J., and
Weyand, C. M. (2007). Functional
proﬁle of activated dendritic cells
in unstable atherosclerotic plaque.
Basic Res. Cardiol. 102, 123–132.
Feig, J. E.,Rong, J. X.,Shamir,R.,Sanson,
M., Vengrenyuk, Y., Liu, J., Rayner,
K., Moore, K., Garabedian, M., and
Fisher, E. A. (2011). HDL promotes
rapid atherosclerosis regression in
mice and alters inﬂammatory prop-
erties of plaque monocyte-derived
cells.Proc.Natl.Acad. Sci.U.S.A. 108,
7166–7171.
Galkina,E.,Kadl,A., Sanders, J.,Varugh-
ese, D., Sarembock, I. J., and Ley,
K. (2006). Lymphocyte recruitment
into the aortic wall before and dur-
ing development of atherosclerosis
is partially L-selectin dependent. J.
Exp. Med. 203, 1273–1282.
Galkina, E., and Ley, K. (2009).
Immune and inﬂammatory mecha-
nisms of atherosclerosis (∗). Annu.
Rev. Immunol. 27, 165–197.
Gautier,E. L.,Huby,T., Saint-Charles, F.,
Ouzilleau, B., Pirault, J., Deswaerte,
V., Ginhoux, F., Miller, E. R., Witz-
tum, J. L., Chapman, M. J., and
Lesnik, P. (2009). Conventional den-
dritic cells at the crossroads between
immunity and cholesterol home-
ostasis in atherosclerosis.Circulation
119, 2367–2375.
Geissmann, F., Gordon, S., Hume, D.
A., Mowat, A. M., and Randolph, G.
J. (2010). Unravelling mononuclear
phagocyte heterogeneity. Nat. Rev.
Immunol. 10, 453–460.
Gerrity, R. G. (1981). The role of the
monocyte in atherogenesis: I. Tran-
sition of blood-borne monocytes
into foam cells in fatty lesions. Am.
J. Pathol. 103, 181–190.
Gleissner, C. A., Shaked, I., Erbel, C.,
Böckle,r D., Katus, H. A., and Ley, K.
(2010a). CXCL4 downregulates the
atheroprotective hemoglobin recep-
tor CD163 in human macrophages.
Circ. Res. 106, 203–211.
Gleissner, C. A., Shaked, I., Little,
K. M., and Ley, K. (2010b). CXC
chemokine ligand 4 induces a
unique transcriptome in monocyte-
derived macrophages. J. Immunol.
184, 4810–4818.
Gordon, S., and Martinez, F. O.
(2010). Alternative activation of
macrophages: mechanism and func-
tions. Immunity 32, 593–604.
Gordon, S., and Taylor, P. R. (2005).
Monocyte and macrophage het-
erogeneity. Nat. Rev. Immunol. 5,
953–964.
Han, J. W., Shimada, K., Ma-Krupa,
W., Johnson, T. L., Nerem, R. M.,
Goronzy, J. J., and Weyand, C. M.
(2008). Vessel wall-embedded den-
dritic cells induce T-cell autoreactiv-
ity and initiate vascular inﬂamma-
tion. Circ. Res. 102, 546–553.
www.frontiersin.org March 2012 | Volume 3 | Article 44 | 11
Butcher and Galkina Dendritic cells and macrophages in atherosclerosis
Hansson,G. K., Bondjers,G., Bylock,A.,
and Hjalmarsson, L. (1980). Ultra-
structural studies on the localization
of IgG in the aortic endothelium and
subendothelial intima of atheroscle-
rotic and nonatherosclerotic rabbits.
Exp. Mol. Pathol. 33, 302–315.
Hermansson, A., Ketelhuth, D. F.,
Strodthoff, D., Wurm, M., Hans-
son, E. M., Nicoletti, A., Paulsson-
Berne, G., and Hansson, G. K.
(2010). Inhibition of T cell response
to native low-density lipoprotein
reduces atherosclerosis. J. Exp. Med.
207, 1081–1093.
Hoff, H. H. (1972). Human intracra-
nial atherosclerosis. A histochemical
and ultrastructural study of gross
fatty steak lesions. Am. J. Pathol. 69,
421–438.
Jonasson, L., Holm, J., Skalli, O., Bond-
jers, G., and Hansson, G. K. (1986).
Regional accumulations of T cells,
macrophages, and smooth muscle
cells in the human atherosclerotic
plaque. Arteriosclerosis 6, 131–138.
Jongstra-Bilen, J., Haidari, M., Zhu, S.
N., Chen, M., Guha, D., and Cybul-
sky, M. I. (2006). Low-grade chronic
inﬂammation in regions of the nor-
mal mouse arterial intima predis-
posed to atherosclerosis. J. Exp.Med.
203, 2073–2083.
Joris, I., Stetz, E., and Majno, G.
(1979). Lymphocytes and mono-
cytes in the aortic intima–An
electron-microscopic study in the
rat. Atherosclerosis 34, 221–231.
Kadl, A., Meher, A. K., Sharma, P. R.,
Lee,M.Y.,Doran,A.C., Johnstone,S.
R., Elliott, M. R., Gruber, F., Han, J.,
Chen,W., Kensler, T., Ravichandran,
K. S., Isakson, B. E., Wamhoff, B.
R., and Leitinger, N. (2010). Identi-
ﬁcation of a novel macrophage phe-
notype that develops in response to
atherogenic phospholipids via Nrf2.
Circ. Res. 107, 737–746.
Khallou-Laschet, J.,Varthaman,A., For-
nasa, G., Compain, C., Gaston, A.
T., Clement, M., Dussiot, M., Lev-
illain, O., Graff-Dubois, S., Nico-
letti, A., and Caligiuri, G. (2010).
Macrophage plasticity in experi-
mental atherosclerosis. PLoS ONE 5,
e8852.
Kleemann, R., Zadelaar, S., and Koois-
tra, T. (2008). Cytokines and athero-
sclerosis: a comprehensive review of
studies in mice. Cardiovasc. Res. 79,
360–376.
Ley, K., Miller, Y. I., and Hedrick, C. C.
(2011). Monocyte and macrophage
dynamics during atherogenesis.
Arterioscler. Thromb. Vasc. Biol. 31,
1506–1516.
Lewkowich I. P., Lajoie S., Clark J.
R., Herman N. S., Sproles A. A.,
and Wills-Karp M. (2008). Allergen
uptake, activation, and IL-23 pro-
duction by pulmonary myeloid DCs
drives airway hyperresponsiveness
in asthma-susceptible mice. PLoS
ONE 3, e3879.
Liao, X., Sharma, N., Kapadia, F., Zhou,
G., Lu, Y., Hong, H., Paruchuri, K.,
Mahabeleshwar, G. H., Dalmas, E.,
Venteclef, N., Flask, C. A., Kim, J.,
Doreian, B. W., Lu, K. Q., Kaestner,
K. H., Hamik, A., Clement, K., and
Jain, M. K. (2011). Kruppel-like fac-
tor 4 regulates macrophage polariza-
tion. J. Clin. Invest. 121, 2736–2749.
Liu, K., Victora, G. D., Schwickert, T.
A., Guermonprez, P., Meredith, M.
M., Yao, K., Chu, F. F., Randolph,
G. J., Rudensky, A. Y., and Nussen-
zweig, M. (2009). In vivo analysis
of dendritic cell development and
homeostasis. Science 324, 392–397.
Llodra, J., Angeli, V., Liu, J., Trogan,
E., Fisher, E. A., and Randolph, G.
J. (2004). Emigration of monocyte-
derived cells from atherosclerotic
lesions characterizes regressive, but
not progressive, plaques. Proc. Natl.
Acad. Sci. U.S.A. 101, 11779–11784.
Ma-Krupa, W., Jeon, M. S., Spoerl,
S., Tedder, T. F., Goronzy, J. J.,
and Weyand, C. M. (2004). Activa-
tion of arterial wall dendritic cells
and breakdown of self-tolerance in
giant cell arteritis. J. Exp. Med. 199,
173–183.
Manthey, H. D., and Zernecke, A.
(2011). Dendritic cells in atheroscle-
rosis: functions in immune regula-
tion and beyond. Thromb. Haemost.
106, 772–778.
Martinez, F. O., Gordon, S., Locati, M.,
and Mantovani, A. (2006). Tran-
scriptional proﬁling of the human
monocyte-to-macrophage differen-
tiation and polarization: new mol-
ecules and patterns of gene expres-
sion. J. Immunol. 177, 7303–7311.
Matsuura, E., Kobayashi, K., Tabuchi,
M., and Lopez, L. R. (2006). Oxida-
tive modiﬁcation of low-density
lipoprotein and immune regulation
of atherosclerosis.Prog. LipidRes. 45,
466–486.
Matta, B. M., Castellaneta, A., and
Thomson,A. W. (2010). Tolerogenic
plasmacytoid DC. Eur. J. Immunol.
40, 2667–2676.
Millonig, G., Niederegger, H., Rabl,
W., Hochleitner, B. W., Hoefer, D.,
Romani, N., and Wick, G. (2001).
Network of vascular-associated den-
dritic cells in intimaof healthy young
individuals. Arterioscler. Thromb.
Vasc. Biol. 21, 503–508.
Moore, K. J., and Tabas, I. (2011).
Macrophages in the pathogenesis of
atherosclerosis. Cell 145, 341–355.
Mosser, D. M., and Edwards, J. P.
(2008). Exploring the full spectrum
of macrophage activation. Nat. Rev.
Immunol. 8, 958–969.
Murray, P. J., and Wynn, T. A. (2011).
Protective and pathogenic functions
of macrophage subsets. Nat. Rev.
Immunol. 11, 723–737.
Naik, S. H., Metcalf, D., van Nieuwen-
huijze,A.,Wicks, I.,Wu, L.,O’Keeffe,
M., and Shortman K. (2006).
Intrasplenic steady-state dendritic
cell precursors that are distinct
from monocytes. Nat. Immunol. 7,
663–671.
Nakajima, K., Yamashita, T., Kita,
T., Takeda, M., Sasaki, N., Kasa-
hara, K., Shinohara, M., Rikitake,
Y., Ishida, T., Yokoyama, M., and
Hirata, K. (2011). Orally adminis-
tered eicosapentaenoic acid induces
rapid regression of atherosclerosis
via modulating the phenotype of
dendritic cells in LDL receptor-
deﬁcient mice. Arterioscler. Thromb.
Vasc. Biol. 31, 1963–1972.
Nakashima Y., Plump A. S., Raines
E. W., Breslow J. L., and Ross R.
(1994).ApoE-deﬁcientmice develop
lesions of all phases of ather-
osclerosis throughout the arter-
ial tree. Arterioscler. Thromb. 14,
133–140.
Niessner, A., Sato, K., Chaikof, E. L.,
Colmegna, I., Goronzy, J. J., and
Weyand, C. M. (2006). Pathogen-
sensing plasmacytoid dendritic cells
stimulate cytotoxic T-cell func-
tion in the atherosclerotic plaque
through interferon-alpha. Circula-
tion 114, 2482–2489.
Niessner, A., and Weyand, C. M. (2010).
Dendritic cells in atherosclerotic dis-
ease. Clin. Immunol. 134, 25–32.
Onai, N., Obata-Onai, A., Tussi-
wand, R., Lanzavecchia, A., and
Manz MG. (2006) Activation of
the Flt3 signal transduction cas-
cade rescues and enhances type I
interferon-producing and dendritic
cell development. J. Exp. Med. 203,
227–238.
Otterbein, L. E., Soares, M. P.,
Yamashita, K., and Bach, F. H.
(2003). Heme oxygenase-1: unleash-
ing the protective properties of
heme. Trends Immunol. 24, 449–455.
Packard, R. R., Maganto-Garcia, E.,
Gotsman, I., Tabas, I., Libby, P., and
Lichtman, A. H. (2008). CD11c(+)
dendritic cells maintain antigen
processing,presentation capabilities,
and CD4(+) T-cell priming efﬁcacy
under hypercholesterolemic condi-
tions associatedwith atherosclerosis.
Circ. Res. 103, 965–973.
Paulson, K. E., Zhu, S. N., Chen, M.,
Nurmohamed, S., Jongstra-Bilen, J.,
and Cybulsky, M. I. (2010). Resident
intimal dendritic cells accumulate
lipid and contribute to the initia-
tion of atherosclerosis.Circ. Res. 106,
383–390.
Perrin-Cocon, L., Coutant, F., Agau-
gue, S., Deforges, S., Andre, P.,
and Lotteau, V. (2001). Oxidized
low-density lipoprotein promotes
mature dendritic cell transition
from differentiating monocyte. J.
Immunol. 167, 3785–3791.
Pulendran B., Smith J. L., Caspary G.,
Brasel K., Pettit D., Maraskovsky E.,
and Maliszewski C. R. (1999). Dis-
tinct dendritic cell subsets differen-
tially regulate the class of immune
response in vivo. Proc. Natl. Acad.
Sci. U.S.A. 96, 1036–1041.
Randolph, G. J. (2009). The fate
of monocytes in atherosclerosis. J.
Thromb. Haemost. 7, 28–30.
Reizis, B., Bunin, A., Ghosh, H. S.,
Lewis, K. L., and Sisirak, V. (2011).
Plasmacytoid dendritic cells: recent
progress and open questions. Annu.
Rev. Immunol. 29, 163–183.
Sato, K., Niessner, A., Kopecky, S. L.,
Frye, R. L., Goronzy, J. J., and
Weyand, C. M. (2006). TRAIL-
expressing T cells induce apoptosis
of vascular smooth muscle cells in
the atherosclerotic plaque. J. Exp.
Med. 203, 239–250.
Smith, J. D., Trogan, E., Ginsberg,
M., Grigaux, C., Tian, J., and Miy-
ata, M. (1995). Decreased athero-
sclerosis in mice deﬁcient in both
macrophage colony-stimulating fac-
tor (op) and apolipoprotein E.
Proc. Natl. Acad. Sci. U.S.A. 92,
8264–8268.
Stanley, E. R., Chen, D. M., and Lin, H.
S. (1978). Induction of macrophage
production and proliferation by a
puriﬁed colony stimulating factor.
Nature 274, 168–170.
Stary H. C., Chandler A. B., Dins-
more R. E., Fuster V., Glagov S.,
Insull W., Rosenfeld M. E., Schwartz
C. J., Wagner W. D., and Wissler
R. W. (1995). A deﬁnition of
advanced types of atherosclerotic
lesions and a histological classiﬁca-
tionof atherosclerosis.A report from
the Committee on Vascular Lesions
of the Council on Arteriosclero-
sis, American Heart Association.
Arterioscler. Thromb. Vasc. Biol. 15,
1512–1531.
Stein, M., Keshav, S., Harris, N.,
and Gordon, S. (1992). Inter-
leukin 4 potently enhances murine
macrophage mannose receptor
activity: a marker of alterna-
tive immunologic macrophage
activation. J. Exp. Med. 176,
287–292.
Frontiers in Physiology | Vascular Physiology March 2012 | Volume 3 | Article 44 | 12
Butcher and Galkina Dendritic cells and macrophages in atherosclerosis
Steinman, R. M. (2007). Dendritic
cells: understanding immunogenic-
ity. Eur. J. Immunol. 37, S53-S60.
Steinman, R. M., Hawiger, D., and
Nussenzweig, M. C. (2003). Tolero-
genic dendritic cells. Annu. Rev.
Immunol. 21, 685–711.
Stoneman, V., Braganza, D., Figg,
N., Mercer, J., Lang, R., God-
dard, M., and Bennett, M. (2007).
Monocyte/macrophage suppression
in CD11b diphtheria toxin recep-
tor transgenic mice differentially
affects atherogenesis and established
plaques. Circ. Res. 100, 884–893.
Swirski, F. K., Weissleder, R., and
Pittet, M. J. (2009). Heteroge-
neous in vivo behavior of mono-
cyte subsets in atherosclerosis. Arte-
rioscler. Thromb. Vasc. Biol. 29,
1424–1432.
Tabas, I. (2010). Macrophage death and
defective inﬂammation resolution in
atherosclerosis. Nat. Rev. Immunol.
10, 36–46.
Villadangos, J. A., and Young, L.
(2008). Antigen-presentation
properties of plasmacytoid
dendritic cells. Immunity 29,
352–361.
Waltner-Romen, M., Falkensammer, G.,
Rabl, W., and Wick, G. (1998). A
previously unrecognized site of local
accumulation of mononuclear cells.
The vascular-associated lymphoid
tissue. J. Histochem. Cytochem. 46,
1347–1350.
Weber, C., Meiler, S., Doring, Y., Koch,
M., Drechsler, M., Megens, R. T.,
Rowinska, Z., Bidzhekov, K., Fecher,
C., Ribechini, E., van Zandvoort, M.
A., Binder, C. J., Jelinek, I., Hris-
tov, M., Boon, L., Jung, S., Korn, T.,
Lutz, M. B., Forster, I., Zenke, M.,
Hieronymus, T., Junt, T., and Zer-
necke, A. (2011). CCL17-expressing
dendritic cells drive atherosclero-
sis by restraining regulatory T cell
homeostasis in mice. J. Clin. Invest.
121, 2898–2910.
Wolfs, I. M., Donners, M. M., and
de Winther, M. P. (2011). Differ-
entiation factors and cytokines
in the atherosclerotic plaque
micro-environment as a trigger for
macrophage polarisation. Thromb.
Haemost. 106, 763–771.
Wu, H., Gower, R. M., Wang, H., Per-
rard, X. Y., Ma, R., Bullard, D. C.,
Burns, A. R., Paul, A., Smith, C. W.,
Simon, S. I., and Ballantyne, C. M.
(2009). Functional role of CD11c+
monocytes in atherogenesis associ-
ated with hypercholesterolemia. Cir-
culation 119, 2708–2717.
Zhu, S. N., Chen, M., Jongstra-Bilen,
J., and Cybulsky, M. I. (2009).
GM-CSF regulates intimal cell pro-
liferation in nascent atheroscle-
rotic lesions. J. Exp. Med. 206,
2141–2149.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 20December 2011; paper pend-
ing published: 12 January 2012; accepted:
20 February 2012; published online: 19
March 2012.
Citation: Butcher MJ and Galkina EV
(2012) Phenotypic and functional hetero-
geneity of macrophages and dendritic cell
subsets in the healthy and atherosclerosis-
prone aorta. Front. Physio. 3:44. doi:
10.3389/fphys.2012.00044
This article was submitted to Frontiers
in Vascular Physiology, a specialty of
Frontiers in Physiology.
Copyright © 2012 Butcher and Galkina.
This is an open-access article distributed
under the terms of the Creative Commons
Attribution Non Commercial License,
which permits non-commercial use, dis-
tribution, and reproduction in other
forums, provided the original authors and
source are credited.
www.frontiersin.org March 2012 | Volume 3 | Article 44 | 13
